Clinical trials: Neurodegenerative Disorders
Parkinson Disease
Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a…
- Trial name
- NCT03368170
- Testing
- Mesdopetam (IRL790)
- Where
- 20 sites in Sweden, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Integrative Research Laboratories AB
Parkinson's Disease (PD)
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT04380142
- Testing
- ABBV-951, Levodopa/Carbidopa (LD/CD)
- Where
- 76 sites in United States, Australia
- Volunteers
- 174 people
- Sponsor
- AbbVie
Mitochondrial Diseases
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
A long-term extension study to assess the safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases who previously enrolled into study…
- Trial name
- NCT02473445
- Testing
- Cysteamine Bitartrate
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen
Amyotrophic Lateral Sclerosis
A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis
People with Amyotrophic Lateral Sclerosis (ALS) will use a P300 based brain computer interface (BCI) keyboard to type in assistive technology devices.
- Trial name
- NCT01119001
- Testing
- P300 Brain Computer Interface Keyboard
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Michigan
Alzheimer's Disease
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.
- Trial name
- NCT02185053
- Testing
- CPC-201
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Parkinson's Disease
Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations
This is a multicentre, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of Perampanel (E2007) as an adjunctive therapy in levodopa treated PD subjects with motor fluctuations.
- Trial name
- NCT00505622
- Testing
- Perampanel
- Where
- France
- Volunteers
- 328 people
- Sponsor
- Eisai Limited
Parkinson's Disease
Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease
Background: Long-term management of Parkinson's disease (PD) does not reach its full potential due to lack of knowledge about disease progression.
- Trial name
- NCT02474329
- Testing
- Clinical assessment, Fox Insight self-monitoring android app and falls detector
- Where
- Netherlands
- Volunteers
- 304 people
- Sponsor
- Radboud University Medical Center
Parkinson's Disease
A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants
The objective of this clinical trial was to evaluate the safety and tolerability of adeno-associated virus (AAV)-mediated delivery of glutamic acid decarboxylase (GAD) gene transfer into the subthalamic nuclei (STN) of…
- Trial name
- NCT05603312
- Testing
- AAV-GAD Low Dose, AAV-GAD High Dose
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- MeiraGTx, LLC
Alzheimer Disease
Imaging Inflammation in Alzheimer's Disease With 11C-ER176
This study is being done to learn about inflammation in the brain of those with Alzheimer's disease (AD). The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with…
- Trial name
- NCT03744312
- Testing
- 11C-ER176, Florbetaben
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Columbia University
Amyotrophic Lateral Sclerosis
A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
- Trial name
- NCT05039099
- Testing
- AP-101
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 73 people
- Sponsor
- AL-S Pharma
Amyotrophic Lateral Sclerosis
A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the long-term safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis who were previously randomized, received treatment, and completed the…
- Trial name
- REViVALS-1B (NCT05176093)
- Testing
- Engensis
- Where
- 2 sites in United States, South Korea
- Volunteers
- 8 people
- Sponsor
- Helixmith Co., Ltd.
Alzheimer's Disease
DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).
- Trial name
- DHA (NCT00440050)
- Testing
- DHA (Docosahexaenoic Acid)
- Where
- 51 sites in United States
- Volunteers
- 402 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Dementia, Vascular, Alzheimer Disease
LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers
The proposed Phase 2 project will involve the further development and evaluation of LEAD IT!, which is a tablet-based app designed to enable persons with dementia to lead activities for their peers (i.e., other persons with…
- Conditions
- Dementia, Vascular, Alzheimer Disease, Dementia, Mixed
- Trial name
- NCT05516342
- Testing
- LEAD IT! Programming
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- Hopeful Aging
Amyotrophic Lateral Sclerosis
Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)
About 213 people with ALS will participate in this study. There will be locations in North and South America. During the first part, participants will be randomly assigned to a group (like by flipping a coin).
- Trial name
- NCT03068754
- Testing
- Acthar
- Where
- 69 sites in United States, Argentina and 5 more
- Volunteers
- 143 people
- Sponsor
- Mallinckrodt
Friedreich's Ataxia
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
The purpose of this long term extension study is to evaluate the long-term safety of ACTIMMUNE® (interferon-γ 1b) in participants with Friedreich's Ataxia (FA).
- Trial name
- STEADFAST (NCT02797080)
- Testing
- interferon γ-1b
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Amgen
Amyotrophic Lateral Sclerosis
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month…
- Trial name
- MITOTARGET (NCT00868166)
- Testing
- Olesoxime, Riluzole
- Where
- 15 sites in Belgium, France and 3 more
- Volunteers
- 512 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).
- Trial name
- BeyoND (NCT02726386)
- Testing
- ND0612
- Where
- 57 sites in United States, Austria and 7 more
- Volunteers
- 214 people
- Sponsor
- NeuroDerm Ltd.
Orthostatic Hypotension, Parkinson's Disease
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease.
- Trial name
- 306A/306B (NCT01176240)
- Testing
- Droxidopa
- Where
- 60 sites in United States
- Volunteers
- 225 people
- Sponsor
- Chelsea Therapeutics
Tuberous Sclerosis Complex, Seizures
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P.
- Trial name
- NCT02544750
- Testing
- GWP42003-P
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Jazz Pharmaceuticals
Alzheimer's Disease
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01369225
- Testing
- AAB-003 (PF-05236812)
- Where
- 21 sites in United States, South Korea
- Volunteers
- 52 people
- Sponsor
- Pfizer